Qualys (QLYS) News Roundup for Nov. 7–8, 2025: Analyst Upgrade, EPS Estimate Lift, and Stock Holds Near $150 After Q3 Beat

Qualys (QLYS) News Roundup for Nov. 7–8, 2025: Analyst Upgrade, EPS Estimate Lift, and Stock Holds Near $150 After Q3 Beat

Dateline: November 8, 2025 — Cybersecurity vendor Qualys, Inc. (NASDAQ: QLYS) stayed in the headlines heading into the weekend, with fresh analyst reactions following Tuesday’s earnings beat, a state pension fund disclosing a larger stake, and continued chatter around its agentic‑AI roadmap. Below is a concise, Google News–ready digest of everything new about Qualys published November 7–8, 2025.


Key Points at a Glance

  • Upgrade today: Wall Street Zen shifted QLYS to “Buy.” (MarketBeat summary). MarketBeat
  • Forecast lift: William Blair raised its Q1‑2026 EPS estimate to $1.26 (from $1.12), citing stronger near‑term profitability. (MarketBeat summary). MarketBeat
  • Institutional activity (Nov. 7):STRS Ohio disclosed it boosted its Qualys holdings last quarter. (MarketBeat filing brief). MarketBeat
  • Price context (today):QLYS last traded around $149.73; 52‑week range $112.61–$159.73, per Reuters. Reuters
  • Why the attention: On Nov. 4, Qualys beat Q3 expectations and raised full‑year guidance (revenue to $665.8–$667.8M; non‑GAAP EPS to $6.93–$7.00). PR Newswire

Today — Saturday, Nov. 8, 2025

Analyst upgrade to “Buy.” MarketBeat reports that Wall Street Zen upgraded Qualys shares to Buy today, pointing to the company’s updated FY25 outlook following this week’s results. While this is one datapoint among a mixed street view, upgrades often keep post‑earnings momentum in focus. MarketBeat

EPS estimate raised. In a separate note highlighted by MarketBeat, William Blair lifted its Q1‑2026 EPS estimate to $1.26 (from $1.12). That upward revision reflects improving operating leverage after Qualys’ Q3 delivery and updated guide. MarketBeat

Price snapshot. As of today, Reuters shows QLYS around $149.73, with a 52‑week band of $112.61–$159.73—placing shares closer to the upper end of their one‑year range post‑earnings. Reuters

Momentum chatter. A Saturday technical read from StockTradersDaily flagged “near‑term strong sentiment” but noted a neutral medium‑ to long‑term setup—another sign traders are still digesting this week’s results. Stock Traders Daily

Media mention (AI angle). Yahoo Finance featured a weekend story on “under‑the‑radar” AI names that included Qualys, citing its work on agentic AI in risk operations—an area the company formally unveiled over the summer. Yahoo Finance


Friday, Nov. 7, 2025

State fund adds to QLYS. MarketBeat’s filing roundup says STRS Ohio increased its Qualys stake last quarter. The position change lands one day after Qualys’ report and may be read as a confidence marker from a large institution. MarketBeat

Earnings coverage continues. Yahoo Finance recapped the beat on both revenue (~$170M) and statutory EPS ($1.39), echoing the core numbers investors have been trading on since Tuesday’s release. Yahoo Finance

Investor explainer piece. Simply Wall St also published a Friday analysis noting shares were sharply higher post‑print and reiterating the updated outlook, keeping the story in front of retail investors into the weekend. Simply Wall St

From the Qualys blog (Nov. 7). The company posted a fresh technical write‑up on a large automotive data‑leak case study, tying it to cloud‑misconfiguration lessons for AWS users—useful context for customers evaluating the platform’s risk‑reduction chops. Qualys


Context: What Qualys Reported on Nov. 4 (and Why It Matters)

  • Q3 FY25 results:Revenue $169.9M (+10% YoY); non‑GAAP EPS $1.86; GAAP EPS $1.39; Adjusted EBITDA $82.6M with stronger gross and operating margins. PR Newswire
  • Q4 FY25 guide: Revenue $172–$174M; non‑GAAP EPS $1.73–$1.80. PR Newswire
  • Full‑year FY25 guide raised: Revenue to $665.8–$667.8M (about 10% YoY growth) and non‑GAAP EPS to $6.93–$7.00. PR Newswire

These numbers underpinned this week’s rally and set the stage for analysts to revisit models into year‑end.


Strategy & Product Backdrop to the AI Mentions

The weekend AI chatter references Qualys’ summer launch of an agentic AI–powered Risk Operations Center, designed to automate risk workflows with a marketplace of cyber risk agents embedded in the Enterprise TruRisk Management platform. That product direction continues to shape how investors categorize Qualys among AI‑levered security names. PR Newswire


What’s Next on the Calendar

Qualys management is slated to appear at the UBS Global Technology & AI Conference in Scottsdale on Dec. 2, 2025 (2:15 p.m. MT), with a webcast via the company’s investor relations site—another venue where commentary on billings, platform adoption and AI may surface. Qualys


Bottom Line

For Nov. 7–8, 2025, the new, incremental developments are an upgrade to Buy, a higher near‑term EPS estimate, fresh institutional‑holder interest, and continued media focus on Qualys’ agentic‑AI positioning. All of it layers on top of Tuesday’s clean beat and raised FY25 guide, helping keep QLYS trading near $150 into the weekend. Reuters


Disclosure: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities.

Stock Market Today

  • Insider trim at AnaptysBio after 260% rally prompts investor questions
    January 11, 2026, 6:55 PM EST. AnaptysBio shares rise, but an insider sale by director J. Anthony Ware adds a cautionary note. On Dec. 23, Ware sold 3,900 shares for $193,342.50, trimming direct holdings by 28.82% to 9,630 shares, per an SEC Form 4 filing that discloses insider trades. The sale was in the open market with no indirect holdings, signaling a personal profit-taking move rather than a corporate action. The stock closed at $50.04 after a roughly 264% one-year surge, giving AnaptysBio a market cap around $1.39 billion. This marks Ware's first open-market sale in the period. For investors, the key question is whether the insider trim signals fading enthusiasm or routine profit-taking after a stellar run. AnaptysBio focuses on antibody therapies, including imsidolimab, rosnilimab, and ANB032, with partners like GSK and BMS.
EOSE News Today (Nov 8, 2025): Analyst Downgrade Caps Volatile Week After Record Q3; Warrants Jump as New Orders Build
Previous Story

EOSE News Today (Nov 8, 2025): Analyst Downgrade Caps Volatile Week After Record Q3; Warrants Jump as New Orders Build

Sling TV adds 159,000 subscribers in Q3 2025 as $4.99 Day/Weekend/Week Passes and new $19.99 “Select” tier drive ~11% sequential growth
Next Story

Sling TV adds 159,000 subscribers in Q3 2025 as $4.99 Day/Weekend/Week Passes and new $19.99 “Select” tier drive ~11% sequential growth

Go toTop